Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

2.

Modified personalized cancer vaccine generates powerful immune response

3.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

4.

Congress Ditched Fix to Medicare Doc Pay Cut in Skinny Budget Bill

5.

Patients value communication skills from cancer surgeons across six key areas, according to research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot